EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF

Evotec SE

Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 8, 2026

$1.42+0.04 (+2.90%)

Close on Oct 19, 2026

Dividends

Evotec has not reported a dividend

No dividend per share appears in Evotec's annual filings since fiscal 2018.

Where these numbers come from

Parsed from the XBRL in Evotec's annual and quarterly filings with the SEC
Per-share figures adjusted for the 4-for-1 split on Oct 20, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVO.

Revenue growth2.0% · median 17.5%

Operating margin-17.9% · median -71.4%

Company	Revenue	Growth
EVO	€796.97M	+2.0%
RARE	$717.21M	+17.5%
PTGX	$281.99M	+34.8%
HCM	$204.89M	-4.3%
AAPG	–	–
TLX	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 4,553
Auditor: BDO AG Wirtschaftsprufungsgesellschaft
SEC CIK: 1412558

Advertisement
300 × 250